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letrozole has recently taken favor as a first-line adjuvant treatment for hormone-responsive breast 32 cancer in middle-aged women. Though patient response to letrozole has generally been positive, 33
there is conflicting evidence surrounding its effects on the development of depression. It is 34 possible that the potential adverse effects of letrozole on mood are a result of the impact of 35 hormonal fluctuations on neurogenesis in the hippocampus. Thus, to clarify the effects of 36 letrozole on the hippocampus and behavior, we examined how chronic administration affects 37 hippocampal neurogenesis and depressive-like behavior in middle-aged, intact female mice. 38 Mice were given either letrozole (1mg/kg) or vehicle by injection (i.p.) daily for 3 weeks. 39 Depressive-like behavior was assessed during the last 3 days of treatment using the forced swim 40
test, tail suspension test, and sucrose preference test. The production of new neurons was 41 quantified using the immature neuronal marker doublecortin (DCX), and cell proliferation was 42 quantified using the endogenous marker Ki67. We found that letrozole increased DCX and Ki67 43 expression and maturation in the dentate gyrus, but had no significant effect on depressive-like 44
behavior. Our findings suggest that a reduction in estrogens in middle-aged females increases 45 hippocampal neurogenesis without any adverse impact on depressive-like behavior; as such, this 46 furthers our understanding of how estrogens modulate neurogenesis, and to the rationale for the 47 utilization of letrozole in the clinical management of breast cancer. 48 49 50
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Estrogen-suppressive therapy is a common and effective adjuvant treatment of hormone-57 responsive breast cancer in postmenopausal women. Letrozole, a non-steroidal aromatase 58 inhibitor (AI) that prevents the conversion of androgens into estrogens in the final steps of the 59 estrogen-synthesis pathway, is a first-line treatment of choice. Despite its demonstrated benefits 60 on breast cancer progression, there is conflicting clinical and pre-clinical evidence regarding its 61 adverse effects on mood and cognition. Recently, the effects of letrozole on cognition have 62 attracted more attention, but the evidence for its effects on depression is less understood. Behavioral Testing occurred during days 18-20 of 21 days of letrozole or saline 114 treatment, with the exception of the Sucrose Preference Test, which was administered weekly. A 115 timeline of the procedures is shown in Figure 1A . An Estrous cycle phase was determined as described previously (Brummelte and Galea, 2010 with drug treatment (letrozole or vehicle) as the between-subjects factor and behavior (immobile, 218 mobile), region (dorsal, ventral) or cell type (type 1,2,3) as within-subjects factor with age as a 219 covariate. Serum 17β-estradiol levels, uterine mass and adrenal mass were analyzed using a 220 student's t-test. Percent sucrose preference and percent change in body mass were analyzed with 221 a repeated measures ANOVA with drug treatment as the between-subjects factor and week as the 222 within-subjects factor. Post-hoc analyses used the Newman-Keuls test, and a priori tests utilized 223
Bonferroni corrections. We also tested for violations of normality (Kolmogorov-Smirnov test) 224
and homogeneity of variance for each variable. These assumptions were not violated, so 225 parametric statistics were conducted. Pearson product moment correlations were also conducted 226 on variables of interest. In the FST, TST, or SPT there were no significant differences in behaviors between groups 264 (all p's > 0.15, Figure 3A -C). 265 Adrenal mass (g) 0.0063±0.0008 0.007±0.0002
Figure 3 A-C:
17β-estradiol levels (pg/ml) 18.9±1.9 14.4± 1.5* 287 * Significantly different from saline-treated groups. 288
Correlations 289
There were no significant correlations between neurogenesis markers and behavior (P's >0.3). 290
Discussion 291
We found that letrozole increased the density of immature neurons in the ventral dentate 292 gyrus of middle aged females. This is consistent with findings that long-term ovariectomy in 293 middle-aged female rats increased, while estrogens decreased the survival of immature neurons 294 (Barha et al., 2015) . Additionally, we found that letrozole lowered the proportion of the least 295 mature DCX-expressing neurons. This suggests that letrozole increased the rate of maturation of 296 immature neurons, promoting survival past the proliferative phase into the intermediate and post-297 mitotic phase, consistent with a trend for letrozole to increase type 2 DCX-expressing cells. As 298 DCX is expressed for 28 days in mice (Snyder et al., 2009 ), this would have entailed that some 299 of the more mature cells were produced without letrozole exposure. However, when we 300 examined cell proliferation using the endogenous marker Ki67, we found that letrozole increased 301 cell proliferation in the dentate gyrus, regardless of region. Ki67 is expressed for approximately 302 24 h in every part of the cell mitotic cycle except for G 0 and the initial stages of G 1 . The 303 discrepancy between the length of expression of Ki67 and DCX (1 day and up to 28 days, 304 respectively), likely accounts for the opposing effects seen on DCX-expressing type 1 cells 305
versus Ki67-expressing, as type 1 cells likely expressed DCX for a longer timeframe. It is also 306 important to acknowledge that Ki67 may have been influenced by TST, whereas type 1 DCX 307 cells could have been influenced throughout the last 4 days of behavior testing. It is also possible 308 that the stress effects associated with behavior testing could influence Ki67 expression. 309
However, females do not normally show a decrease in cell proliferation in response to acute 310 stress (Falconer and Galea, 2003, Tzeng et al., 2014) , unlike males (Falconer and Galea, 2003, 311 Tzeng et al., 2014). Finally, we find no significant correlations between Ki67-expression and 312 immobility in the TST or FST. The lack of association between variables suggests that the stress 313 of testing did not influence Ki67 expression in middle-aged female mice. 314
Studies from the Rune laboratory have found that letrozole decreases cell proliferation in 315 hippocampal cultures taken from postnatal day 5 Wistar rats (Fester et al., 2006) and decreases 316 synapses in immature (postnatal day 9) and adult intact female Wister rats (Bender et al., 2010) . 317
These findings are consistent with our findings that letrozole decreased the percentage of 318 proliferative (Type 1) DCX-expressing cells, but inconsistent with our results that chronic 319 letrozole increased cell proliferation (Ki67-expressing cells). However, these findings taken all 320 together, suggest that there are age and possibly sex-related differences in the effects of letrozole 321 on cell proliferation and neurogenesis in the hippocampus. Future studies should determine the 322 impact of chronic letrozole on the survival of new neurons independent of its effects on cell 323 proliferation, in an age-and sex-dependent manner. 324
Interestingly, letrozole's effects on the density of DCX-expressing cells were seen 325 exclusively in the ventral hippocampus. The ventral hippocampus is implicated in modulating 326 stress and affect (Fanselow and Dong, 2010 and rats in the FST (Molendijk and de Kloet ER, 2019) but to our knowledge no one has 349 described the differences in baseline immobility time as a function of mice versus rats. In the 350 future, the issue of interpretation of the FST would benefit from a careful review of the literature 351 on FST findings in mice versus rats. Future studies should consider the effects of letrozole on 352 depressive-like behavior in the context of a challenge such as chronic stress or cancer, because 353 situations that increase inflammation could impact the effects of letrozole and may provide more 354 robust effects on behavior. 355 It is possible that an increase in testosterone that accompanies aromatase inhibition is 356 responsible for mitigating negative behavioral effects of estrogen depletion. We did attempt to 357 measure serum testosterone in this study, but the levels in serum were below detection threshold 358 in middle-aged females and future studies should examine testosterone levels in brain after 359 chronic letrozole treatment in middle-aged female mice. Castrated male rats are more susceptible 360
to developing depressive-like endophenotypes following chronic stress (Wainwright et al., 361 2011) . Similarly, in men, hypogonadism is associated with depressive symptoms, and androgen 362 treatment can ameliorate these symptoms (Zarrouf et al., 2009 ). Furthermore, testosterone given 363 to surgically menopausal women can elevate mood (Sherwin, 1988) . Further studies could 364 evaluate the role of testosterone on mood after aromatase inhibition in middle-aged females. 365
Finally, in our study we saw no significant effects of letrozole on depressive-like or coping 366 strategies in middle-aged females, but other studies have seen effects of acute letrozole on 367 memory in female mice (Tuscher et al., 2016) and the testing of the effects of chronic letrozole 368 on decision making may be warranted. 369 370 5. Conclusion 371 372
We demonstrate that in middle-aged female mice, chronic letrozole increased 373 hippocampal neurogenesis but had no effect on depressive-like behavior. Future studies could 374 investigate more behaviors that may be regulated by ventral neurogenesis in the hippocampus 375 such as fear motivated learning (Dalla et al., 2009 
